



The Canadian Vaccine Catalogue

Working Group Meeting

April 29, 2021

Agenda



1. CVC Release & Other Updates
2. COVID-19 Terminology Discussion
 - a. Update on COVID-19 concepts
 - b. RFCs for upcoming COVID-19 vaccines
 - c. Discussion
3. Other RFC updates
4. CVC Working Group Terms of Reference and Work Plan
5. Wrap up and questions


1. Release Update

- CVC version 1.1.9 released today, which includes:
 - COVID-19 vaccine lot/expiry information up until April 28th, 2021
 - All vaccine product lot/expiry information for March 2021
 - NOVAVAX COVID-19 trade name concept
 - COVID-19 protein subunit vaccine generic concept
 - Updated MAH for RabAvert trade name concept
 - Addition of IMVAMUNE trade name concept

- Next CVC release (Version 1.1.10)
 - Scheduled for May 13th, 2021

2a. COVID-19 Terminology: Concepts created to date

COVID-19 Terminology Hierarchy



2a. New COVID-19 Vaccine Terminology

Generic Agent Concept - COVID-19 protein subunit vaccines

ConceptID	29291000087103
Concept Name	Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant protein antigen
Preferred Term	COVID-19 protein subunit unspecified

Trade Name Concept - NOVAVAX COVID-19 Vaccine

ConceptID	29171000087106
Concept Name	NOVAVAX COVID-19 VACCINE 0.5 milliliter suspension for injection Novavax Inc.
Preferred Term	COVID-19 NOVAVAX COVID-19 VACCINE NOV

2a. New COVID-19 Vaccine Terminology

Antigen Concept - created by CHI to support COVID-19 protein subunit generic concept

ConceptID	29301000087104
Concept Name	Antigen of Severe acute respiratory syndrome coronavirus 2 recombinant protein
Preferred Term	SARS-CoV-2 recombinant protein antigen

Should the CVC adopt this concept?

2b. RFCs for upcoming COVID-19 vaccines

Generic Agent Concept - COVID-19 virus-like particle

Proposed FSN	Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 virus-like particle
Proposed PT	COVID-19 virus-like particle unspecified
Definition of proposed concept:	A more granular, generic concept to identify COVID-19 vaccines using this technology platform. This is similar to the generic concepts created for COVID-19 mRNA, COVID-19 non-replicating vector, and COVID-19 protein subunit vaccines.

Trade Name Concept - Medicago COVID-19 Vaccine

Proposed FSN	MEDICAGO COVID-19 Vaccine 3.75 micrograms suspension for injection Medicago Inc.
Proposed PT	COVID-19 MEDICAGO COVID-19 VACCINE MED

2c. COVID-19 Terminology Discussion

- Generic agent abbreviation - do we need to be more specific?
- Any other items to discuss re: COVID-19 terminology?

3. Other RFC Updates

1. Create RFC for new concept "Pharmacy Intern (PHINT)"
 - a. To be added to the HealthCareProviderRoleType subset as they are administering vaccines in Ontario
2. GamaSTAN RFC
 - a. RFCs created to change the name of existing concept to "GamaSTAN S/D"; create a new concept for GamaSTAN

4. Terms of Reference & CVC Work Plan

- Overview/confirmation of ToR
- Medium/long-term work plan of the CVC
 - Facilitating barcode scanning (manufacturers have started to publish GTIN data to the CVC)
 - Other work items?

5. Wrap up and Questions

- Next CVC Meeting
 - Thursday, May 27th, 2021 from 2-3PM EST
 - Register in advance for this meeting:
<https://infoway-inforoute.zoom.us/meeting/register/tJEtfuCtqj0iE9FjNVMOp0Y7giY6Swpr9P4k>